See more : Kernex Microsystems (India) Limited (KERNEX.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Tenaya Therapeutics, Inc. (TNYA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tenaya Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Eighty Jewellers Limited (EIGHTY.BO) Income Statement Analysis – Financial Results
- Nippon Life India Asset Management Limited (NAM-INDIA.NS) Income Statement Analysis – Financial Results
- Salesforce, Inc. (CRM.NE) Income Statement Analysis – Financial Results
- The Procter & Gamble Company (PRG.DE) Income Statement Analysis – Financial Results
- Kyoei Sangyo Co.,Ltd. (6973.T) Income Statement Analysis – Financial Results
Tenaya Therapeutics, Inc. (TNYA)
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| Gross Profit | -8.69M | -8.71M | -4.03M | -2.48M | -1.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.04M | 94.54M | 54.39M | 31.10M | 23.15M |
| General & Administrative | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.16M | 31.08M | 18.41M | 7.81M | 4.56M |
| Other Expenses | 0.00 | 2.00K | -23.00K | 430.00K | 1.03M |
| Operating Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Cost & Expenses | 131.19M | 125.62M | 72.81M | 38.91M | 27.71M |
| Interest Income | 7.06M | 1.95M | 108.00K | 87.00K | 453.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.69M | 8.71M | 4.03M | 2.48M | 1.99M |
| EBITDA | -122.51M | -114.95M | -68.70M | -36.43M | -25.72M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -131.19M | -125.62M | -72.81M | -38.91M | -27.71M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.11M | 1.96M | 85.00K | 517.00K | 1.48M |
| Income Before Tax | -124.08M | -123.67M | -72.72M | -38.40M | -26.23M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.96K | -3.07M | -87.00K | -453.00K |
| Net Income | -124.08M | -123.66M | -69.65M | -38.31M | -25.78M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| EPS Diluted | -1.68 | -2.76 | -1.69 | -0.93 | -0.63 |
| Weighted Avg Shares Out | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
| Weighted Avg Shares Out (Dil) | 73.79M | 44.82M | 41.29M | 41.12M | 41.12M |
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates
Why Earnings Season Could Be Great for Tenaya Therapeutics (TNYA)
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
Tenaya Therapeutics Provides 2022 Business Updates
Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture
Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress
Source: https://incomestatements.info
Category: Stock Reports